#1
#1 out of 298.13%
business3h ago
Key facts: Gilead buys Tubulis for $3.15B; remdesivir vs Bundibugyo
- Gilead to acquire Tubulis for $3.15 billion upfront, with up to $1.85 billion in milestones.
- The deal will bring next‑gen ADC platforms and lead assets TUB‑040 and TUB‑030 to Gilead’s oncology pipeline.
- Separately, UT lab tests indicate remdesivir activity against Bundibugyo ebolavirus, possibly stronger than against the Zaire strain.
- Gilead has not responded to the Bundibugyo report at this time.
- The Tubulis deal enhances Gilead’s oncology strategy with ADC technology.
- The transaction includes upfront cash plus potential milestone payments.
- Remdesivir shows activity against Bundibugyo ebolavirus in UT lab tests.
- The Bundibugyo finding could influence views on antiviral efficacy pending validation.
- The source article provides background on Gilead's latest corporate action and unrelated antiviral note.
- The news context covers latest moves in oncology and viral research intersecting investor interests.
Vote 0
